Cargando…

Advances in TRP channel drug discovery: from target validation to clinical studies

Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes e...

Descripción completa

Detalles Bibliográficos
Autores principales: Koivisto, Ari-Pekka, Belvisi, Maria G., Gaudet, Rachelle, Szallasi, Arpad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442523/
https://www.ncbi.nlm.nih.gov/pubmed/34526696
http://dx.doi.org/10.1038/s41573-021-00268-4
_version_ 1783753024921927680
author Koivisto, Ari-Pekka
Belvisi, Maria G.
Gaudet, Rachelle
Szallasi, Arpad
author_facet Koivisto, Ari-Pekka
Belvisi, Maria G.
Gaudet, Rachelle
Szallasi, Arpad
author_sort Koivisto, Ari-Pekka
collection PubMed
description Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels.
format Online
Article
Text
id pubmed-8442523
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84425232021-09-15 Advances in TRP channel drug discovery: from target validation to clinical studies Koivisto, Ari-Pekka Belvisi, Maria G. Gaudet, Rachelle Szallasi, Arpad Nat Rev Drug Discov Review Article Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels. Nature Publishing Group UK 2021-09-15 2022 /pmc/articles/PMC8442523/ /pubmed/34526696 http://dx.doi.org/10.1038/s41573-021-00268-4 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Koivisto, Ari-Pekka
Belvisi, Maria G.
Gaudet, Rachelle
Szallasi, Arpad
Advances in TRP channel drug discovery: from target validation to clinical studies
title Advances in TRP channel drug discovery: from target validation to clinical studies
title_full Advances in TRP channel drug discovery: from target validation to clinical studies
title_fullStr Advances in TRP channel drug discovery: from target validation to clinical studies
title_full_unstemmed Advances in TRP channel drug discovery: from target validation to clinical studies
title_short Advances in TRP channel drug discovery: from target validation to clinical studies
title_sort advances in trp channel drug discovery: from target validation to clinical studies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442523/
https://www.ncbi.nlm.nih.gov/pubmed/34526696
http://dx.doi.org/10.1038/s41573-021-00268-4
work_keys_str_mv AT koivistoaripekka advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies
AT belvisimariag advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies
AT gaudetrachelle advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies
AT szallasiarpad advancesintrpchanneldrugdiscoveryfromtargetvalidationtoclinicalstudies